GlobalTort

GlobalTort

The Intersection Among Torts, Science, Corporate Law, Insurance & Bankruptcy

Category Archives: Cancer

Subscribe to Cancer RSS Feed

Genomics and Actual Protein Output: Collaboration to Perform Large-Scale Protein Analysis of up to 40,000 Human Samples

Posted in Cancer, Litigation Industry, Science
More and more molecular data will arrive over the next few years; some of it will be very valuable for more deeply understanding when and how diseases arise. Consider, for example, the fact that genes matter a great deal because they contain the instructions for producing proteins, but we need to know more about actual… Continue Reading

“Cancer Rights Law: An Interdisciplinary Approach” by Bryant and Morales (2018) – Cyber Monday – 40% Off:

Posted in Cancer, Pro Bono
Today is the perfect day to buy a copy of “Cancer Rights Law: An Interdisciplinary Approach.” Why. Because today is the ABA’s annual cyber sale, with 40% off for law books and other written materials. This 2018 book was written  by the leaders of Triage Cancer, working with the ABA for publication.  Triage Cancer is… Continue Reading

Arsenic in Drinking Water, Cancer and Age of Exposure

Posted in Cancer, Litigation Industry, Mass Tort Issues, Science
Age of exposure to toxins is receiving increasing attention from researchers. Below, the abstract from an interesting study of arsenic drinking water exposures in Chile. https://academic.oup.com/aje/article-abstract/187/11/2297/5063615#.W98xc7qmSq8.email “Abstract Arsenic in drinking water is known to cause cancer and noncancer diseases, but little is known about its association with age at exposure. Here, we investigated age at… Continue Reading

New Article Touches on Genomics and Causation as to Mesothelioma

Posted in Asbestos, Cancer, Mass Tort Issues, Science
It’s good to see more lawyers focused on genomics as related to causation in mass tort cases. A group from Goldberg Segalla just wrote about the topic as part of a broader paper on alternative causation issues. The article was published in Mealey’s Asbestos; it is: Defense Strategies For Alternative Causation Arguments In Asbestos Case, … Continue Reading

Notable New Study and Paper on 198 Persons with Mesotheliomas and Germline Variants in Cancer Associated Genes

Posted in Asbestos, Cancer, Science
Some scientific findings provide both opportunities and risks for litigants in mass tort cases. The point is highlighted by a new paper by Panou and colleagues published in mid- August in the Journal of Clinical Oncology. The paper concludes that a significant proportion (12%) of patients with malignant mesotheliomas carry inherited (germline) mutations in cancer-associated… Continue Reading

Free Online Access to Evidence from Glyphosate Trial (Johnson Case)

Posted in Cancer, Litigation Industry, Mass Tort Issues, Science
For those of us who are junkies for trials involving alleged or actual toxins, there’s a good resource online for the ongoing Johnson trial involving glyphosate/RoundUp.  The plaintiff’s firm for the ongoing Round Up trial  (the Johnson case) seems to be posting pretty much everything online at the firm’s web site; trial exhibits, trial transcripts… Continue Reading

“Jury awards $12M for failure to diagnose lung cancer”

Posted in Cancer, Medical Malpractice
Caps on medical malpractice verdicts raise real issues of due process, right to trial and fundamental fairness. Therefore, it seems appropriate to occasionally publicize med mal cases that illustrate the incredible human burdens created by medical errors that could be remedied with better systems that actually require follow-up. Accordingly, here’s the full text of  a… Continue Reading

“Nightingale Health & UK Biobank announce major initiative to analyze 500,000 blood samples” in 30 months for 200 biomarkers

Posted in Cancer, Science
We continue to see increases in the the scale and pace of the development of molecular and genetic knowledge. A recent example arises from the announcement of serious plans for detailed analysis of 500,000 blood samples for 200 biomarkers. That’s impressive by itself. Then, note the related factors. The new data will be related back… Continue Reading

Before issuing an award, jury asks: “Can we punish the defendants by requiring them to place a warning label on their products?”

Posted in Cancer, Litigation Industry, Mass Tort Issues, Punitives
Yesterday’s punitive damages verdict against J&J arrived after interesting questions from the jury to the court. One wonders how J&J will account for the questions on a going forward basis. As reported by LAW360, the questions were as set out below: “Law360, Los Angeles (May 24, 2018, 1:09 PM EDT) — A California jury found… Continue Reading

Mesothelioma Therapy – Preliminary Report – 1 Complete Response

Posted in Asbestos, Cancer, Science
Therapy with CAR-T cells (artificially modified t-cells) is a “hot” idea these days in cancer therapy.  Last week, the Mesothelioma Applied Research Foundation highlighted some early days, limited success in researchers at MMSK using CAR T cells in a clinical trial setting involving treatment of persons suffering from mesotheliomas; see this May 18, 2018 article. … Continue Reading

Author Jock McCulloch Dies of Mesothelioma

Posted in Asbestos, Cancer
Jock McCulloch (and colleagues) wrote multiple books attacking companies that manufactured and/or sold asbestos-containing products in Australia or South Africa.  They include Asbestos – Its Human Cost (1986),  Asbestos Blues: Labour, Capital, Physicians & The State in South Africa (2002), and Defending the Indefensible (2008).   As fate would have it, he died of mesothelioma on January 18, 2018 in Melbourne.… Continue Reading

“Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033”

Posted in Asbestos, Cancer
A recent article explains that mesotheliomas in South Korea are projected to increase over the years ahead, mainly because of demographics, according to these authors. The article is  “Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.” The abstract explains: “Malignant mesothelioma is a malignant tumor on the pleura or the peritoneum… Continue Reading

Cells – as Recorders of Events

Posted in Cancer, Science
The molecular revolution continues, with continuing implications for improving our understanding of how external events effect our cells.  As part of that journey, a group of researchers recently used CRISPR to embed a video into DNA and then retrieve it from the DNA, as described in a July 12, 2017 article at Stat News.  Why?… Continue Reading

Manville Trust Transparency – Data from David Austern

Posted in Asbestos, Asbestos Bankruptcy, Cancer
In the good old days, there was more asbestos trust transparency as to overall statistics for the Manville Trust. One reason for the transparency was presentations by David Austern at asbestos litigation conferences. As an example, consider this detailed set of data showing claims by disease for the “pre-1995 period” up through 2001.  The data… Continue Reading

Will You Pick Your Next Jury Using Relatively Instant Artificial Intelligence (AI)?

Posted in Artificial Intelligence (AI), Cancer, Litigation Industry, Mass Tort Issues
Suppose your next jury trial involves issues about cancer. Will you be able to use AI and big data – during jury selection – to quickly find all of a possible juror’s social media comments about cancer? Check out this April 26, 2017 article at Artificial Lawyer about a firm trying to make that happen.… Continue Reading

Perrin Conferences May 15 Webinar: JURORS, GENOMICS AND TORT LITIGATION WEBINAR: BREAKING DOWN THE SCIENCE OF GENOMICS FOR JURORS, ATTORNEYS AND THE BENCH

Posted in Asbestos, Cancer
Researchers continue to identify more and more genes that appear relevant to development of mesothelioma. Are you experts and trial team ready? If not, consider the upcoming webinar described below. JURORS, GENOMICS AND TORT LITIGATION WEBINAR: BREAKING DOWN THE SCIENCE OF GENOMICS FOR JURORS, ATTORNEYS AND THE BENCH Monday, May 15, 2017 2:00 – 3:30pm… Continue Reading

Got 500k Leukemia and Lymphoma Genomes?

Posted in Cancer, Litigation Industry, Mass Tort Issues
Imagine all the data, hypotheses and conclusions that will emerge from sequencing 500k biobanked leukemia and lymphoma tumors … Imagine the implications for workers compensation and civil litigation if there are associated work histories. Pasted below is the full text of the March 8, 2017 press release. ______________________ Munich Leukemia Laboratory Selects IBM Watson and… Continue Reading

Jurors In Toxic Tort Litigation Take Genetics Seriously

Posted in Asbestos, Cancer, Litigation Industry, Mass Tort Issues, Science
In the shameless self-promotion department, another article on “omics” and torts. LAW360 kindly published this on February 21, 2017.  In my view, it’s critical for trial lawyers to get focused on a range of topics related to “omics” and toxic torts. Jurors In Toxic Tort Litigation Take Genetics Seriously Share us on: Law360, New York… Continue Reading